IP Library › Granted Patent US 12,364,742
Granted Patent B2
US 12,364,742 · App. 17/388,606 · Granted Jul 22, 2025

Antigen-specific T cells for inducing immune tolerance

Inventors: David W. Scott (Bethesda, MD); Yongchan Kim (Rockville, MD); Aihong Zhang (Ellicott City, MD)
Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
A61K39/0008A61K40/11A61K40/22A61K40/42A61P3/10A61P21/04A61P37/06C12N5/0637C12N5/0638A61K2239/31A61K2239/38C12N2502/1107C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,742
App. No.
17/388,606
Granted
Jul 22, 2025
Kind
B2
Abstract

Described herein are agents and methods for targeting antigen-specific B cells using engineered T cells, such as regulatory T cells or cytotoxic T cells, or bi-specific antibodies. The agents and methods can be used to reduce undesirable immune responses.

Claims (5)

1. A method of targeting antigen-specific B cells, comprising exposing B cells specific to a target antigen to regulatory T cells that are transduced with a B-cell-targeting antibody receptor (BAR) construct comprising (i) a target antigen or a domain thereof from human clotting factor VIII, factor IX, and myelin basic protein (MBP) and (ii) an intracellular signaling domain selected from the group consisting of CD28-CD3 zeta, 4-1BB, and ICOS recognized by said antigen-specific B cells.

2. The method of claim 1 , wherein the regulatory T cells are selected from CD4 + CD25 hi CD127 lo Foxp3 + regulatory T cells, CD4 + CD25 hi CD127 lo Foxp3 + Helios + regulatory T cells, CD4 + CD25 hi Foxp3 + regulatory T cells, and CD4+CD25 hi Foxp3 + Helios + regulatory T cells.

3. The method of claim 1 , wherein the method is effected in a patient suffering from or at risk of developing an undesirable hemophilia immune response to said target antigen.

4. The method of claim 3 , wherein said patient is receiving a biotherapeutic treatment for a genetic disease selected from hemophilia.

5. The method of claim 1 , wherein said target is selected from the group consisting of a C2 domain of human clotting factor VIII, an A2 domain of human clotting factor VIII, and an A2-C2 domain of human clotting factor VIII.

Assignments (5)
SECURITY INTEREST Recorded Jul 18, 2023
From: BOUNCE MERGER SUB II, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 064298/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2021
From: SCOTT, DAVID W.
To: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
Reel/Frame 058248/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2021
From: KIM, YONGCHAN
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 058248/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2021
From: ZHANG, AIHONG
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 058248/0580 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2021
From: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 058248/0604 →
Continuity (5)
Division 15780584
Provisional Application 62393245 · Sep 12, 2016
Provisional Application 62359886 · Jul 8, 2016
Provisional Application 62263108 · Dec 4, 2015
Related Publication 20220054608A1 · Feb 24, 2022
References Cited (55)
US 7214785B2 · Nakashima et al. · 2007 [cited by applicant]
US 10093901B2 · Scott · 2018 [cited by examiner]
US 11090373B2 · Scott · 2021 [cited by examiner]
US 20130116182A1 · Pratt · 2013 [cited by examiner]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20150017141A1 · June et al. · 2015 [cited by applicant]
US 20160264662A1 · Dimitrov et al. · 2016 [cited by applicant]
WO WO2012079000A1 · 2012 [cited by examiner]
Colman et al., Research in Immunology 145(1): 33-36 (Year: 1994). [cited by examiner]
Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522-527 (Year: 2008). [cited by examiner]
Greenspan et al., Nature Biotechnology 17: 936-937 (Year: 1999). [cited by examiner]
Dodson et al., Nature 450: 176-177 (Year: 2007). [cited by examiner]
Landry et al., J Mol Biol 308: 883-893 (Year: 2001). [cited by examiner]
Goebels et al., Brain 123: 508-518 (Year: 2000). [cited by examiner]
Adair et al., “Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision,” Frontiers in Immunology, 2017, vol. 8(1117), pp. 1-10. [cited by applicant]
Dang et al., “1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocytes activation,” The Journal of Immunology, 1991, vol. 147(9), pp. 2825-2832, T… [cited by applicant]
Daraiavach et al., “Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains,” European Journal of Immunology, 1988, vol. 18(12), pp… [cited by applicant]
De Wit et al., “Antigen-Specific B Cells Reactivate an Effective Cytotoxic T Cell Response against Phagocytosed [cited by applicant]
Edwards et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a single Protein, BLys,” J Mol Biol, 2003, vol. 334(1), pp. 103-118, Elsevier, Amsterd… [cited by applicant]
Ellebrechtl et al., “Desmoglein 3 chimeric autoantibody receptor T cells a novel strategy for immunotherapy of pemphigus vulgaris (THER2P.958)”, The Journal of Immunology, May 2015, vol. 194, (1 Supplement), 67.9, (Abst… [cited by applicant]
Extended European Search Report for European Application No. 16871218.0 dated Jun. 6, 2019. [cited by applicant]
Fransson et al., “CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery”, Journal of Neuroinflammation, Jan. 2012, vol. 9(1), pp. 1-12, XP0551 08972. [cited by applicant]
Graw et al., “Haemophilia A: From Mutations Analysis To New Therapies,” Nature Review Genetics, 2005, vol. 6, pp. 488-501, Nature Publishing Group, Berlin, Germany. [cited by applicant]
Harper et al., “CTLA-4 And CD28 Activated Lymphocyte Molecules Are Closely Related In Both Mouse And Human As To Sequence, Message Expression, Gene Structure, And Chromosomal Location,” The Journal of Immunology, 1991, … [cited by applicant]
Hutloff et al., “ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,” Nature, 1999, vol. 397, pp. 263-266, Macmillan Magazines Ltd, London, United Kingdom. [cited by applicant]
Kim et al., “Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses”, Blood, Feb. 2015, vol. 125(7), pp. 1107-1115 (available online Dec. 2014}. [cited by applicant]
Kim et al., “Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion”, Blood, Mar. 22, 2012, vol. 119, pp. 2810-2818. [cited by applicant]
Kwon et al., “cDNA sequences of two inducible T-cell genes,” Proc. Natl. Acad. Sci., 1989, vol. 86, pp. 1963-1967. [cited by applicant]
Lacroix-Desmazes et al., “Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A”, Blood, Jul. 2008, vol. 112(2), pp. 240-249. [cited by applicant]
Lafage-Pochitaloff et al., “Human CD28 and CTLA-4 lg superfamily genes are located on chromosome 2 at bands q33-q34,” Immunogenetics, 1990, vol. 31, pp. 198-201, Springer-Verlag, Berlin, Germany. [cited by applicant]
Lee et al., “T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial”, The Lancet, Feb. 2015, vol. 385, pp. 517-528. [cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engineering, Design & Selection, 2009, vol. 22(3),… [cited by applicant]
Maus et al., “Antibody-modified T cells: CARs take the front seat for hematologic malignancies”, Blood, Apr. 2014, vol. 123(17), pp. 2625-2635, XP055278960. [cited by applicant]
Miao et al., “CD4+ FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice”, Blood, Nov. 2009, vol. 114(19), pp. 4034-4444. [cited by applicant]
Naumann et al., “Generation and Characterization of FVIII-Specific CAR-Transduced Regulatory T Cells”, Blood, Dec. 2014, vol. 124(21), p. 236, (Abstract only), XP055590739. [cited by applicant]
NCBI, “ [cited by applicant]
NCBI, “ [cited by applicant]
NCBI, “ [cited by applicant]
NCBI, “ [cited by applicant]
NCBI, “ [cited by applicant]
NCBI, “ [cited by applicant]
Osman et al., “Evidence from an association between the T cell receptor/CD3 antigen complex and the CD5 antigen in human T lymphocytes,” Eur. J. Immunol., 1992, vol. 22, pp. 2995-3000, Wiley-VCH, Weinheim, Germany. [cited by applicant]
Parvathaneni et al., “BAR-CD8 T-Cell Mediated Targeted Killing of Inhibitor Producing FVIII-Specific B Cells”, Blood, Dec. 2015, vol. 126(23), p. 294 (Abstract only), XP055590702. [cited by applicant]
Pincus et al., “Characterization of T Cells Bearing HLA-DR Antigens in Rheumatoid Arthritis”, Arthritis and Rheumatism, Jan. 1985, vol. 28(1), pp. 517-528. [cited by applicant]
Skupsky et al., “Role of Adaptive Regulatory T Cells in the Induction of Tolerance to FVIII”, Blood, 2008, vol. 112(11), p. 1027 (Abstract). [cited by applicant]
Thorburn et al., “Harnessing Regulatory T cells to Suppress Asthma”, American Journal of Respiratory Cell and Molecular Biology, Nov. 2010, vol. 43(5), pp. 511-519, XP055032545. [cited by applicant]
Truett et al., “Characterization of the Polypeptide Composition of Human Factor VIII:C and the Nucleotide Sequence and Expression of the Human Kidney cDNA,” DNA, 1985, vol. 4(5), pp. 33-349, Mary Ann Liebert, Inc., New … [cited by applicant]
Weissman et al., “Molecular cloning and chromosomal localization of the human T-cell receptor chain: Distinction from the molecular CD3 complex,” Proc. Natl. Acad. Sci., 1988, vol. 85, pp. 9709-9713. [cited by applicant]
Wroblewska et al., “Dangerous liaisons: how the immune system deals with factor VIII”, Journal of Thrombosis and Haemostasis, Jan. 27, 2013, vol. 11, pp. 47-55. [cited by applicant]
Zhang “Targeting antigen-specific B cells using BAR-transduced cytotoxic and regulatory T cells”, The American Association of Immunologists, Inc., May 2016, presentation. [cited by applicant]
Zhang et al., “Subsets of regulatory T cells and their roles in allergy”, Journal of Translational Medicine, Biomed Central, May 2014, vol. 12(1), p. 125, XP021186612. [cited by applicant]
Zhang et al., “Targeting antigen-specific B cells using BAR-transduced cytotoxic and regulatory T cells”, The Journal of Immunology, May 2016, vol. 196(1), Supplement 70.7 (available online Apr. 2016). [cited by applicant]
Zhou et al., “Characterization of human homologue of 4-1BB and its ligand,” Immunology Letters, 1995, vol. 45, pp. 67-73, Elsevier Science B.V., Amsterdam, Netherlands. [cited by applicant]
Zucker et al., “Factor VIII-related antigen in human blood platelets: localization and release by thrombin and collagen,” J. Lab. Clin. Med., 1979, vol. 94(5). pp. 675-682. [cited by applicant]
References Are Not Being Filed Herewith. They Are Already of Record in One or More of the Following Applications, Which Are for Priority Under 35 U.S.C. Section 120 (see 37 C.F.R. Section 1.98(d)(1)): U.S. Appl. No. 15/… [cited by applicant]